Loading...
XSHE
002826
Market cap597mUSD
Jun 16, Last price  
23.40CNY
1D
4.23%
1Q
108.56%
Jan 2017
-10.96%
IPO
143.75%
Name

Tibet Aim Pharm Inc

Chart & Performance

D1W1MN
P/E
279.03
P/S
6.44
EPS
0.08
Div Yield, %
0.13%
Shrs. gr., 5y
-0.20%
Rev. gr., 5y
6.42%
Revenues
667m
-22.14%
221,107,828290,726,213346,995,393451,922,477380,292,645488,774,206553,255,391602,619,263725,459,075856,734,307667,038,997
Net income
15m
-65.14%
19,706,88532,372,67150,029,90455,358,45060,476,62425,255,04137,328,95041,091,16442,476,49144,135,40915,386,479
CFO
167m
+143.79%
52,240,3962,184,178057,179,40177,288,00613,313,86459,202,426101,735,689109,522,21068,453,222166,880,943
Dividend
May 31, 20240.03 CNY/sh

Profile

Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.
URL
http://www.emyy.cn/
IPO date
Dec 09, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
667,039
-22.14%
856,734
18.10%
Cost of revenue
583,311
789,287
Unusual Expense (Income)
NOPBT
83,728
67,447
NOPBT Margin
12.55%
7.87%
Operating Taxes
7,874
10,587
Tax Rate
9.40%
15.70%
NOPAT
75,854
56,860
Net income
15,386
-65.14%
44,135
3.91%
Dividends
(20,281)
(19,007)
Dividend yield
0.89%
0.98%
Proceeds from repurchase of equity
(22)
(2,642)
BB yield
0.00%
0.14%
Debt
Debt current
11,011
50,051
Long-term debt
Deferred revenue
6,604
4,432
Other long-term liabilities
1,862
Net debt
(417,413)
(271,231)
Cash flow
Cash from operating activities
166,881
68,453
CAPEX
(3,181)
Cash from investing activities
(43,002)
Cash from financing activities
(59,303)
27,592
FCF
133,411
115,859
Balance
Cash
385,856
321,283
Long term investments
42,567
1
Excess cash
395,071
278,446
Stockholders' equity
517,398
517,316
Invested Capital
372,603
512,273
ROIC
17.14%
10.48%
ROCE
10.91%
8.53%
EV
Common stock shares outstanding
192,331
190,678
Price
11.87
16.49%
10.19
-6.94%
Market cap
2,282,969
17.50%
1,943,006
-6.71%
EV
1,870,598
1,676,477
EBITDA
107,864
90,148
EV/EBITDA
17.34
18.60
Interest
1,178
811
Interest/NOPBT
1.41%
1.20%